The complex study conducted by the research group over the years has bridged the gap in cholinergic strategies in AD, showing that not considering CHRFAM7A could lead to the rejection of drug candidates that could be beneficial for 25% of AD patients (Szigeti et al., 2020). This evidence concerns the gene CHRFAM7A and Alzheimer disease.